专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA2772328C NOVEL FORMS OF A MULTICYCLIC COMPOUND 未知
公开(公告)号：CA2772328C
公开(公告)日：2017-06-20
申请号：CA2772328
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： The present invention provides alternative forms of Compound I, (see Compound I) processes to reproducibly make them and methods of treating patients using them.

2. 发明专利

ES2572652T3 Nuevas formas de un compuesto multicíclico 未知
公开(公告)号：ES2572652T3
公开(公告)日：2016-06-01
申请号：ES10750210
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： Forma cristalina del Compuesto I que tiene la Fórmula**Fórmula** en donde la forma cristalina es: (A) a. la Forma A0 se caracteriza por un patrón de difracción de rayos X de polvo que comprende uno o más de los siguientes picos: 4.32, 6.07, 8.55, 12.07 y 15.37 ± 0.2 grados 2-theta; o (B) a. la Forma HC0 se caracteriza por un patrón de difracción de rayos X de polvo que comprende uno o más de los siguientes picos: 8.36, 8.71, 16.69, 17.39 y 24.59 ± 0.2 grados 2-theta; o b. la Forma HD0 se caracteriza por un patrón de difracción de rayos X de polvo que comprende uno o más de los siguientes picos: 7.60, 8.99 y 15.16 ± 0.2 grados 2-theta; o una mezcla de estos.

3. 发明专利

SG178852A1 NOVEL FORMS OF A MULTICYCLIC COMPOUND 未知
公开(公告)号：SG178852A1
公开(公告)日：2012-04-27
申请号：SG2012012290
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
摘要： Alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them.

4. 发明专利

DK2470540T3 Hidtil ukendte former af en multicyklisk forbindelse 未知
公开(公告)号：DK2470540T3
公开(公告)日：2016-08-01
申请号：DK10750210
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28

5. 发明专利

UA110604C2 КРИСТАЛІЧНА ФОРМА ПОЛІЦИКЛІЧНОЇ СПОЛУКИ 未知
公开(公告)号：UA110604C2
公开(公告)日：2016-01-25
申请号：UAA201203501
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： АльтернативнікристалічніформисполукиІ, відтворюваніспособиїхотриманняі способилікуванняпацієнтівз їхзастосуванням.

6. 发明专利

EA020756B1 НОВЫЕ ФОРМЫ ПОЛИЦИКЛИЧЕСКОГО СОЕДИНЕНИЯ 未知
公开(公告)号：EA020756B1
公开(公告)日：2015-01-30
申请号：EA201270315
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MAIRTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： Изобретениеотноситсяк кристаллическойформесоединения I, гдекристаллическаяформапредставляетсобой: (А) а) формуА, котораяхарактеризуетсяпорошковойрентгеновскойдифрактограммой, содержащейодинилиболееизследующихпиков: 4,32, 6,07, 8,55, 12,07 и 15,37 ± 0,2 градуса 2-тэта; или (В) a) формуНС, котораяхарактеризуетсяпорошковойрентгеновскойдифрактограммой, содержащейодинилиболееизследующихпиков: 8,36, 8,71, 16,69, 17,39 и 24,59 ± 0,2 градуса 2-тэта; или b) форму HD, котораяхарактеризуетсяпорошковойрентгеновскойдифрактограммой, содержащейодинилиболееизследующихпиков: 7,60, 8,99 и 15,16 ± 0,2 градуса 2-тэта; илиихсмесь. Изобретениетакжеотноситсяк фармацевтическойкомпозициидлялечениярака, содержащейкристаллическуюформусоединения I.

7. 发明专利

HK1171750A1 多環化合物的新形式未知
公开(公告)号：HK1171750A1
公开(公告)日：2013-04-05
申请号：HK12112589
申请日：2012-12-06
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D20060101 , A61K20060101 , A61P20060101

8. 发明专利

CA2772328A1 NOVEL FORMS OF A MULTICYCLIC COMPOUND 未知
公开(公告)号：CA2772328A1
公开(公告)日：2011-03-10
申请号：CA2772328
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： Alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them.

9. 发明专利

AU2010289746B2 Novel forms of a multicyclic compound 未知
公开(公告)号：AU2010289746B2
公开(公告)日：2016-07-07
申请号：AU2010289746
申请日：2010-08-25
申请人： CEPHALON INC
发明人： BIERLMAIER STEPHEN , CHRISTIE MICHAEL , COURVOISIER LAURENT , FIELD R SCOTT , HALTIWANGER R CURTIS , HE LINLI , JACOBS MARTIN J , KRESS MICHAEL , MCKEAN ROBERT E , MOWREY DALE R , PETRAITIS JOSEPH , YAZDANIAN MEHRAN
IPC分类号： C07D487/04 , A61K31/407 , A61P25/28
摘要： Alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them.

10. 发明专利

NZ598883A Crystalline forms of a parp inhibitor compound 未知
公开(公告)号：NZ598883A
公开(公告)日：2014-09-26
申请号：NZ59888310
申请日：2010-08-25
申请人： CEPHALON INC
发明人： KRESS MICHAEL , HE LINLI , COURVOISIER LAURENT , JACOBS MARTIN J , PETRAITIS JOSEPH , BIERLMAIER STEPHEN , HALTIWANGER R CURTIS , MOWREY DALE R , MCKEAN ROBERT E , FIELD R SCOTT , YAZDANIAN MEHRAN , CHRISTIE MICHAEL
IPC分类号： C07D487/04 , A61K31/407 , A61K31/496 , A61P25/28 , C07D295/13
摘要： Disclosed are crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrollo[3,4-c]carbazole-1,3(2H)-dione (Compound I), wherein the crystalline form of Compound I is characterized by (a) an X-ray powder diffraction pattern comprising at least the following peaks: 4.32, 6.07 and 8.55 ± 0.2 degrees 2-theta, and one or more of the following peaks: 12.07 and 15.37 ± 0.2 degrees 2-theta (form A0); (b) an X-ray powder diffraction pattern comprising at least the following peaks: 7.16, 7.89 and 16.54 ± 0.2 degrees 2-theta, and one or more of the following peaks: 10.77 and 21.20 ± 0.2 degrees 2-theta (form B0); (c) an X-ray powder diffraction pattern comprising at least the following peaks: 8.36, 17.39 and 24.59 ± 0.2 degrees 2-theta, and one or more of the following peaks 8.71 and 16.69 ± 0.2 degrees 2-theta (form HC0); (d) a compound of formula I characterized by an X-ray powder diffraction pattern comprising at least the following peaks: 7.60, 8.99, 15.16, 17.99 and 25.00 ± 0.2 degrees 2-theta (form HD0); (e) an X-ray powder diffraction pattern comprising at least the following peaks: 8.56, 14.64, 16.07, 22.24 and 23.02 ± 0.2 degrees 2-theta, and one or more of the following peaks: 9.80, 10.62, 11.04, 12.68, 17.18, 17.23, 19.75, 23.31, 27.06 and 27.85 ± 0.2 degrees 2-theta (form S20); (f) a compound of formula I characterised by an X-ray powder diffraction pattern comprising at least the following peaks: 6.70, 8.67 and 16.80 ± 0.2 degrees 2-theta, and one or more of the following peaks: 7.61, 10.29, 11.57, 13.36, 15.02, 16.85, 17.33 and 25.20 ± 0.2 degrees 2-theta (form S30); (g) a compound of formula I characterised by an X-ray powder diffraction pattern comprising at least the following peaks: 8.42, 8.60 and 13.92 ± 0.2 degrees 2-theta, and one or more of the following peaks: 7.95, 17.20, 21.07, 21.30 and 24.46 ± 0.2 degrees 2-theta (form S40); (h) a compound of formula I characterised by an X-ray powder diffraction pattern comprising at least the following peaks: 8.68, 11.10 and 23.31 ± 0.2 degrees 2-theta, and one or more of the following peaks: 8.36, 15.42, 16.21, 16.94, 17.25, 17.39 and 26.27 ± 0.2 degrees 2-theta (form S60); (i) a compound of formula I characterised by an X-ray powder diffraction pattern comprising at least the following peaks: 8.34, 8.67 and 24.57 ± 0.2 degrees 2-theta, and one or more of the following peaks 16.68 and 17.33 ± 0.2 degrees 2-theta (form S90); (j) a compound of formula I characterised by an X-ray powder diffraction pattern comprising at least the following peaks: 7.63, 7.67 and 24.46 ± 0.2 degrees 2-theta, and one or more of the following peaks: 8.63, 9.00, 14.78, 17.13, 17.39, 17.99 and 18.15 ± 0.2 degrees 2-theta (form S120), and a mixtures thereof. Further disclosed is a process for preparing anhydrous crystalline form A0 of Compound I as defined above, the process comprising the steps of: a. dissolving a non-crystalline form of Compound I in a solvent such as tetrahydrofuran; b. filtering the resulting solution; c. partially distilling the solvent while adding an anti-solvent such as heptane to precipitate Compound I; d. further distilling the resulting slurry while adding additional anti-solvent to reduce the volume of the solvent used in step (a); e. heating the slurry to achieve complete conversion to Form A0; f. cooling; g. collecting the product via filtration; and h. drying. Further disclosed is a pharmaceutical composition comprising a crystalline form of Compound I as defined above or a mixture thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式